Merck KGaA (OTCMKTS:MKGAY) Receives $252.50 Average PT from Analysts

Merck KGaA (OTCMKTS:MKGAYGet Rating) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $252.50.

Several research firms recently weighed in on MKGAY. UBS Group raised shares of Merck KGaA from a “sell” rating to a “neutral” rating in a research report on Monday, February 28th. JPMorgan Chase & Co. dropped their target price on shares of Merck KGaA from €270.00 ($287.23) to €250.00 ($265.96) and set an “overweight” rating for the company in a report on Monday, March 14th.

Shares of MKGAY stock remained flat at $$38.36 on Friday. The business’s 50 day simple moving average is $38.36 and its two-hundred day simple moving average is $38.36. Merck KGaA has a 1 year low of $32.53 and a 1 year high of $42.02.

Merck KGaA Company Profile (Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

Featured Stories

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with's FREE daily email newsletter.